Dr. Reddy's to buy Mayne Pharma’s US generics drug list for at least $90M
Generic drugs giant Dr. Reddy’s Laboratories has made a deal to acquire Mayne Pharma’s US generics portfolio for at least $90 million.
Mayne Pharma sells about 45 different generics products in the US, Dr. Reddy’s said in a release announcing the sale, including generics in women’s health.
Mayne has been working to revamp its portfolio and to support the launch of Nextstellis, a brand-name birth control pill. In August of last year, the company said that the Covid-19 pandemic had left behind its goals for the Nextstellis launch. The generics business has been in decline, echoing struggles the industry has faced across companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.